SCHEMBL6933238

SCHEMBL6933238

CC(=O)N1CC(=S)C[C@H]1C(=O)O.N[C@@H](Cc1ccc(Oc2ccccc2[N+](=O)[O-])cc1)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.38
LTA4H P09960 1/20 0.38
PTGS2 P35354 1/20 0.38
TPH1 P17752 6/20 0.36
ACE P12821 1/20 0.36
KDM4A O75164 1/20 0.36
TACR1 P25103 2/20 0.36
GAA P10253 1/20 0.35
ALPI P09923 1/20 0.35
PKM P14618 1/20 0.35
XIAP P98170 1/20 0.35
SLC7A5 Q01650 1/20 0.35
TNK2 Q07912 1/20 0.35
NR1I2 O75469 1/20 0.34
PPARG P37231 1/20 0.34
AGTR2 P50052 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6931449 0.85 ALDH1A1 (0.39) PTGS1TPH1TACR1GAAALPI
Phenylalanine SCHEMBL7906184 0.82 SLC7A5 (0.52) PTGS1TPH1ACEALPIPKM
SCHEMBL6368433 0.82 PTGS1 (0.51) PTGS1LTA4HPTGS2TPH1KDM4A
SCHEMBL6429072 0.82 PTGS1 (0.51) PTGS1LTA4HPTGS2TPH1KDM4A
SCHEMBL7905125 0.81 ITGB1 (0.43) PTGS1PTGS2TPH1ACEALPI
SCHEMBL6935180 0.81 DPP4 (0.47) PTGS1LTA4HACEALPIPKM
SCHEMBL7904116 0.81 SLC7A5 (0.45) PTGS1TPH1ACEALPIPKM
SCHEMBL6931447 0.81 CTSL (0.40) PTGS1ALPIPKMXIAPSLC7A5
SCHEMBL6934867 0.80 LTA4H (0.39) LTA4HTPH1
SCHEMBL6936891 0.80 S1PR5 (0.47) PTGS1TPH1ACEALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0984981-B1 ANTI-INFLAMMATORY TYROSINE DERIVATIVES CELLTECH THERAPEUTICS LTD (GB) 2003-12-17 EP disclosed
US-6093696-A N-ACETYL-D-THIOPROLINE-(O-2,6-DICHLOROBENZYL)-L-TYROSINE, FOR EXAMPLE; SELECTIVELY INHIBIT THE ALPHA 4 SUBGROUP OF INTEGRINS FROM BINDING TO THEIR LIGANDS; USE IN PROPHYLAXIS OR TREATMENT OF IMMUNE OR INFLAMMATORY DISEASES CELLTECH THERAPEUTICS, LIMITED (GB) 2000-07-25 US disclosed